Be a part of 2^nd Global Experts Meeting on Cell and Gene Therapy

About the Conference

The 2nd Global Experts Meeting on Cell and Gene Therapy, scheduled for June 08–09, 2026, in Paris, France, is an international scientific forum dedicated to accelerating innovation in advanced therapeutic strategies. Anchored by the theme “Advancing medicine by harnessing the power of cells and genes,” the conference focuses on the growing role of cellular and genetic technologies in transforming disease prevention, diagnosis, and treatment.

The scientific agenda spans cutting-edge developments in stem cell therapy, gene delivery systems, genome editing, RNA therapeutics, immunotherapies, regenerative medicine, and personalized treatment approaches. Sessions will explore both fundamental research and clinical translation, addressing manufacturing challenges, regulatory pathways, safety considerations, and real-world implementation. Through expert-led lectures, panel discussions, workshops, and poster presentations, the conference fosters interdisciplinary collaboration and global knowledge exchange. This meeting provides a unique opportunity to shape the future direction of cell and gene therapy in an era of precision and personalized medicine.

Why to Attend

The 2nd Global Experts Meeting on Cell and Gene Therapy offers a premier international platform for professionals committed to advancing next-generation medical therapies. Over two intensive scientific days, participants will gain insights into evolving strategies in cell therapy development, gene modification technologies, immune engineering, and regenerative medicine applications.

The conference provides direct access to global experts presenting the latest research findings, clinical trial outcomes, and translational breakthroughs. Attendees will explore how emerging technologies are reshaping therapeutic design, improving safety profiles, and enabling more precise and durable treatment outcomes. Whether you are a clinician, researcher, industry professional, or academic, this meeting offers an ideal environment to enhance scientific understanding, strengthen professional networks, and stay aligned with innovations driving the future of modern medicine.

Conference Highlights

• Global Leaders in Cell and Gene Therapy:
  Learn from internationally recognized scientists, clinicians, and industry experts who are shaping the future of cellular and genetic medicine.
• Comprehensive Scientific Sessions:
  In-depth discussions covering stem cell therapies, genome editing technologies, RNA-based therapeutics, immunotherapies, regenerative medicine, and translational research.
• Clinical Translation & Manufacturing Insights:
  Sessions focused on clinical trial design, scalability, quality control, regulatory pathways, and real-world implementation of cell and gene therapies.
• Workshops and Interactive Discussions:
  Expert-led sessions emphasizing practical challenges, emerging tools, and innovative therapeutic strategies.
• Industry & Technology Showcase:
  Explore cutting-edge platforms, biotechnologies, delivery systems, and manufacturing solutions presented by leading industry partners.
• Young Researchers & Early-Career Forum:
  Dedicated opportunities for students, fellows, and early-career professionals to present research, receive expert feedback, and gain international exposure.
• Networking & Global Collaboration:
  Connect with multidisciplinary professionals across academia, clinical practice, industry, and regulatory sectors to foster future collaborations.
• Awards & Recognition:
  Honors for outstanding scientific contributions, including Best Research Presentation, Young Investigator Award, Best Clinical Innovation, and Best Poster Presentation.

Track 1: Advances in Cellular Reprogramming & Identity Control

Cellular reprogramming enables mature cells to revert to flexible developmental states. Researchers examine how transcriptional plasticity reshapes lineage commitment. Precise modulation of epigenetic erasure improves stability during conversion. Misregulation of chromatin accessibility can impair therapeutic outcomes. Improved protocols enhance safety in regenerative medicine. Ongoing studies emphasize maintaining functional consistency across reprogrammed cell populations.

Exploration Points:

• Cell Fate Reversal Models
• Reprogramming Efficiency Metrics
• Lineage Stability Control

Track 2: Gene Delivery Systems & Vector Engineering

Efficient gene delivery relies on refined carrier systems that reduce immune activation. Optimization of viral tropism improves tissue specificity. Novel capsid redesign enhances transduction efficiency. Non-integrating platforms limit risks linked to genomic insertion. Delivery precision remains a core translational challenge. Advances in formulation science are improving scalability and storage stability.

Engineering Streams:

• Vector Targeting Strategies
• Payload Capacity Optimization
• Immune Evasion Design

Track 3: Stem Cell Therapy & Regenerative Medicine

Stem cell-based treatments aim to replace damaged tissues with functional cells. Control of self-renewal kinetics ensures long-term efficacy. Directed differentiation minimizes off-target development via lineage priming. Cellular integration depends on microenvironmental signaling. Clinical trials highlight scalability challenges. Standardization of protocols remains essential for clinical reproducibility.

Regeneration Focus:

• Stem Cell Expansion Systems
• Differentiation Pathway Control
• Tissue Integration Dynamics

Track 4: Genome Editing Technologies & Precision Control

Genome editing platforms enable targeted DNA modification with high specificity. Advances in base conversion fidelity reduce unintended mutations. Monitoring double-strand break repair improves safety profiling. Editing accuracy depends on sequence recognition domains. Regulatory oversight is rapidly evolving. Long-term genomic integrity is a growing focus of translational studies.

Editing Dimensions:

• Precision Editing Tools
• Off-Target Risk Assessment
• Therapeutic Validation Models

Track 5: Cell-Based Immunotherapies & Immune Engineering

Engineered immune cells demonstrate strong antitumor potential. Enhancing antigen recognition thresholds improves selectivity. Controlled signal transduction cascades regulate activation intensity. Avoiding cytokine overload remains critical for patient safety. Personalized immune modulation is advancing rapidly. Manufacturing consistency directly influences therapeutic durability.

Immunotherapy Tracks:

• Immune Cell Engineering
• Tumor Recognition Optimization
• Safety Control Mechanisms

Track 6: Gene Therapy for Rare Genetic Disorders

Gene therapy offers long-term solutions for monogenic diseases. Correction efficiency depends on allelic restoration accuracy. Stable expression requires promoter durability. Avoiding transgene silencing improves therapeutic persistence. Early diagnosis enhances treatment success. Longitudinal monitoring informs risk-benefit assessment.

Clinical Targets:

• Inherited Disease Correction
• Expression Stability Models
• Long-Term Safety Monitoring

Track 7: Cell Manufacturing & Bioprocess Optimization

Large-scale cell production demands consistent quality control. Monitoring cellular heterogeneity profiles ensures batch reliability. Optimized bioreactor kinetics improve yield efficiency. Stress-induced metabolic drift can alter functionality. Automation reduces variability risks. Regulatory compliance guides process standardization.

Production Pathways:

• Scale-Up Manufacturing Systems
• Quality Assurance Frameworks
• Process Automation Tools

Track 8: Epigenetic Therapies & Gene Regulation

Epigenetic therapies focus on reversible gene expression control. Targeting histone modification patterns reshapes transcription landscapes. Altered DNA methylation gradients influence disease progression. Precision tools avoid permanent genomic alteration. Therapeutic reversibility offers clinical advantages. Combination approaches are under active investigation.

Regulatory Modules:

• Epigenetic Drug Targets
• Expression Modulation Tools
• Reversibility Assessment

Track 9: RNA-Based Therapeutics & Post-Transcriptional Control

RNA therapies allow transient yet precise gene regulation. Stability improvements enhance mRNA translational efficiency. Control of splice variant selection refines protein outcomes. Avoiding innate immune activation improves tolerability. Rapid development supports personalized medicine. Delivery optimization remains a central focus.

RNA Strategy Areas:

• RNA Stability Engineering
• Delivery Optimization
• Therapeutic Timing Control

Track 10: Cell Therapy Safety & Risk Mitigation

Ensuring safety is central to clinical cell therapy success. Monitoring tumorigenic potential markers prevents adverse outcomes. Detecting clonal expansion anomalies improves long-term surveillance. Controlled cell cycle arrest enhances predictability. Regulatory frameworks continue to evolve. Risk modeling supports clinical decision-making.

Safety Domains:

• Risk Assessment Models
• Long-Term Monitoring Systems
• Regulatory Compliance Standards

Track 11: Gene Therapy in Oncology Applications

Cancer gene therapies aim to disrupt malignant signaling networks. Targeting oncogenic driver suppression halts tumor growth. Enhancing tumor-selective expression minimizes collateral damage. Resistance linked to pathway redundancy remains a challenge. Combination therapies show promise. Clinical trials explore adaptive strategies.

Oncology Tracks:

• Tumor-Specific Targeting
• Resistance Management
• Combination Therapy Design

Track 12: Cell–Cell Communication & Therapeutic Signaling

Intercellular communication influences therapeutic outcomes significantly. Modulation of paracrine signaling loops enhances repair. Dysregulated ligand-receptor coupling contributes to disease states. Mapping signal amplification networks improves intervention design. Systems biology supports modeling efforts. Data integration strengthens predictive accuracy.

Communication Themes:

• Cellular Signaling Networks
• Therapeutic Modulation Models
• Systems-Level Analysis

Track 13: Personalized Gene Therapy & Precision Medicine

Personalized therapies align treatment with individual genetic profiles. Analysis of patient-specific mutational spectra improves targeting accuracy. Tailored expression tuning algorithms optimize dosing. Managing interindividual variability enhances predictability. Data integration drives innovation. Ethical considerations guide implementation.

Precision Pathways:

• Genomic Profiling Tools
• Personalized Treatment Design
• Outcome Prediction Models

Track 14: Exosome-Based Therapeutic Delivery

Exosomes serve as natural carriers for therapeutic cargo. Engineering vesicular cargo sorting improves delivery precision. Controlled membrane fusion dynamics enhance uptake. Avoiding clearance pathway activation increases circulation time. Clinical translation is accelerating. Manufacturing scalability remains under evaluation.

Delivery Streams:

• Exosome Engineering
• Cargo Stability Control
• Targeting Optimization

Track 15: Neurodegenerative Disease Cell Therapies

Cell therapies aim to restore function in degenerating neural tissues. Addressing neuronal synaptic loss remains a priority. Supporting axonal regeneration pathways improves connectivity. Managing glial activation imbalance reduces inflammation. Early intervention improves outcomes. Functional recovery metrics guide assessment.

Neurotherapy Focus:

• Neural Repair Strategies
• Inflammatory Control
• Functional Recovery Metrics

Track 16: CRISPR Innovations & Next-Generation Editing

CRISPR systems continue to evolve with enhanced precision. Refinement of guide RNA specificity reduces errors. New editing window modulation expands applicability. Addressing repair pathway bias improves consistency. Ethical oversight remains essential. Clinical translation requires robust validation.

Innovation Tracks:

• Editing Accuracy Enhancement
• Tool Development
• Ethical Governance

Track 17: Immune Tolerance & Transplant Acceptance

Inducing immune tolerance improves cell therapy persistence. Modulating tolerance induction circuits reduces rejection. Control of alloreactive lymphocyte expansion enhances graft survival. Balancing immune suppression thresholds avoids infection risk. Clinical relevance is growing. Long-term outcomes guide protocol refinement.

Tolerance Strategies:

• Immune Modulation Tools
• Rejection Prevention Models
• Long-Term Acceptance Monitoring

Track 18: Aging, Senescence & Cellular Longevity

Aging therapies target dysfunctional cellular states. Clearing senescent cell accumulation restores tissue function. Regulation of telomere attrition rates influences longevity. Altered stress response pathways drive degeneration. Longevity science intersects with gene therapy. Translational studies are expanding rapidly.

Longevity Themes:

• Senescence Intervention
• Aging Biomarker Analysis
• Regenerative Lifespan Extension

Track 19: Regulatory Science & Clinical Translation

Regulatory science bridges laboratory innovation and patient care. Evaluating clinical endpoint validation ensures efficacy claims. Monitoring manufacturing consistency indices supports approval pathways. Addressing post-market surveillance gaps improves safety. Global harmonization is essential. Stakeholder collaboration strengthens compliance.

Translation Pillars:

• Regulatory Frameworks
• Clinical Trial Design
• Compliance Monitoring

Track 20: Future Directions in Cell & Gene Therapy

Emerging technologies redefine therapeutic boundaries. Integration of synthetic biology circuits enables programmable cells. Predictive computational therapy modeling improves trial efficiency. Adaptive therapeutic feedback systems enhance responsiveness. Collaboration accelerates innovation. Interdisciplinary research shapes next-generation solutions.

Future Horizons:

• Emerging Technology Integration
• Predictive Modeling Tools
• Next-Gen Therapeutic Design

The global cell and gene therapy market is experiencing rapid expansion, driven by advances in molecular biology, regenerative medicine, and precision therapeutics. Increasing prevalence of genetic disorders, cancer, autoimmune diseases, and rare conditions has accelerated demand for innovative treatment modalities that offer long-term or curative outcomes rather than symptomatic management.

Significant investments from pharmaceutical companies, biotechnology firms, and venture capital groups are fueling research, clinical trials, and commercialization efforts. Regulatory agencies across major regions are also introducing adaptive approval pathways to support faster clinical translation while maintaining safety and efficacy standards. As a result, cell and gene therapies are transitioning from experimental treatments to mainstream clinical solutions.

Current market trends indicate a strong shift toward personalized and precision-based therapies, where treatments are tailored to individual genetic and cellular profiles. Advances in genome editing platforms, RNA-based therapeutics, and immune cell engineering are enabling more targeted, durable, and safer interventions. There is also growing emphasis on scalable manufacturing technologies, automation, and standardized quality control to support large-scale clinical deployment.

Global Cell & Gene Therapy Market Growth (USD Billion):

This graph illustrates the steady and accelerated growth of the global cell and gene therapy market over a ten-year period. The market expands from approximately USD 8 billion in 2020 to an estimated USD 65 billion by 2030, reflecting increased clinical approvals, expanded therapeutic indications, and rising investments in regenerative medicine and genetic therapies. The sharp growth beyond 2026 highlights the transition of cell and gene therapies from experimental treatments to established clinical solutions across oncology, rare diseases, and chronic conditions.
 

                                 
 

Cell & Gene Therapy Market Share by Therapy Type (%):

This graph represents the current segmentation of the cell and gene therapy market by therapy type. Gene therapy holds the largest market share at 35%, driven by advancements in genome editing, viral vectors, and rare disease treatments. Cell therapy follows at 30%, supported by regenerative medicine and tissue repair applications. CAR-T and immune cell therapies account for 20%, largely propelled by oncology innovations, while stem cell therapy represents 15%, maintaining strong relevance in regenerative and neurological medicine. The distribution highlights the diverse and rapidly evolving therapeutic landscape.